Viltepso approval date?

When was Viltepso approved?

Viltepso (viltolarsen) was approved by the FDA on August 17, 2019 [1].

What is Viltepso for?

Viltepso is an exon-skipping therapy for Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene amenable to exon 53 skipping [1].

Where to verify approval and regulatory details

You can confirm the approval timing and related regulatory information on DrugPatentWatch.com: [1]

Sources

[1] Viltepso FDA approval date (DrugPatentWatch.com)